Clinical characteristics of people with cystic fibrosis and frequent fungal infection.

Authors:
Poore TS; Meier M; Towler E; Martiniano SL; Brinton JT and 4 more

Journal:
Pediatr Pulmonol

Publication Year: 2021

DOI:
10.1002/ppul.25741

PMCID:
PMC8665034

PMID:
34687280

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Pediatr Pulmonol

Abbreviation: Pediatr Pulmonol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pulmonary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A positive effect of a short period stay in Alpine environment on lung function in asthmatic childr…
Cogo A; Piazza M; Costella S and 6 more (2022) - Transparency Score: 3/6
A successful treatment of a lobar atelectasis in a patient with cystic fibrosis.
Daccò V; Sciarrabba CS; Corti F and 4 more (2022) - Transparency Score: 2/6
A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modu…
Kramer-Golinkoff E; Camacho A; Kramer L and 1 more (2022) - Transparency Score: 3/6
At-home end-tidal carbon dioxide measurement in children with invasive home mechanical ventilation.
Foster CC; Kwon S; Shah AV and 8 more (2022) - Transparency Score: 3/6
Collaborative decision-making: A framework for decision-making about life-sustaining treatments in …
Nageswaran S; Gower WA; Golden SL and 1 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTERESTS Edith T. Zemanick personal fees from Cystic Fibrosis Foundation, site clinical trial support from Vertex Pharmaceuticals and Savara Pharmaceuticals Inc., and material agreements and consulting contracts with Calithera Biosciences and Concert Pharmaceuticals outside the scope of the submitted work. Emily M. DeBoer is a consultant and stockholder for EvoEndoscopy, not related to this project."

Evidence found in paper:

"This project was supported by funding from the Cystic Fibrosis Foundation POORE20D0 (TSP), ZEMANI17Y5 (ETZ), ZEMANI20Y7 (ETZ, MM), NIH/NCATS Colorado CTSA Grant Number UL1 TR002535."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025